LRP5 and colorectal carcinoma: Activation of the LRP5 gene promotes CSC-like phenotypes, including tumorigenicity and platinum-based drug resistance in CRC cells, through activation of the canonical Wnt/β-catenin and IL-6/STAT3 signalling pathways [145].